CARY, NC (July 12, 2022) – Five new companies have joined the CEO Roundtable on Cancer and its campaign to do something more about cancer prevention, diagnosis, and treatment for their employees, their families, and their communities.
The companies include Elligo Health Research®, an accelerator for clinical trials important to cancer care; Black Diamond Therapeutics, a precision oncology medicine company pioneering the discovery and development of therapies for genetically defined cancers with limited treatment options; Change Healthcare, a leading healthcare technology company focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system; Jasper Health, developer of a digital guide for cancer patients; and B&C International, a global business management and consulting firm.
“The diverse areas of focus and expertise of these companies brings great energy and strength to our mutual interest in diminishing the toll of cancer and eventually eliminating this disease that affects so many families,” said William Louv, CEO of the CEO Roundtable on Cancer.
The CEO Roundtable on Cancer (www.ceoroundtableoncancer.org) was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard™ which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to address cancer in the workplace. In 2018, the CEO Roundtable established Project Data Sphere® to accelerate cancer research through its online data platform and data-focused research programs.
“The work of the CEO Roundtable and Elligo Health Research align closely when it comes to facilitating access to the best available cancer treatments and advancing the discovery of new and more effective anti-cancer therapies through clinical trials,” said John Potthoff, Ph.D., CEO of Elligo. “We look forward to partnering to do more to support cancer patients, encourage prevention and improve the chances of eliminating this disease by offering research as care to patients.”
Elligo Health Research® (https://www.elligohealthresearch.com/) accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, their IntElligo® Research Stack technology, and their PatientSelect identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, they accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.
“I am very pleased to be joining the CEO Roundtable on Cancer and to collaborate with such a renowned group of professionals who all share common goals of reducing the risk of cancer and facilitating access to best-in-class treatments,” said David M. Epstein, Co-founder, President and CEO of Black Diamond Therapeutics. “I live this mission daily, but there is still much to be done in addition to discovering and developing novel cancer therapeutics. It is inspiring to see the CEO Roundtable’s commitment to driving significant change in the way we as a society think about the impact of cancer and I look forward to contributing my insights to further these initiatives in the years to come.”
Black Diamond Therapeutics (www.blackdiamondtherapeutics.com) is a precision oncology medicine company pioneering the development of novel MasterKey therapies. They are addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function, and drug discovery. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data to predict and validate oncogenic mutations that promote cancer across tumor types as MasterKey mutations. Black Diamond discovers and develops selective MasterKey therapies against these families of oncogenic mutations.
“I am delighted to be joining the CEO Roundtable on Cancer to work alongside our country’s leading cancer researchers as they drive invaluable improvements for one of healthcare’s most prominent diseases,” said Tim Suther, Senior Vice President & General Manager, Data Solutions, of Change Healthcare.
Change Healthcare is a leading healthcare technology company focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system. They provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient-engagement outcomes in the U.S. healthcare system.
The CEO Roundtable’s Cancer Gold Standard attracted the interest of Jasper Health. The Gold Standard is a workplace wellness accreditation program that offers an evidence-based framework for organizations to provide a healthier workplace by focusing on cancer risk reduction, early detection, and high-quality care.
“Jasper Health strongly believes our partnership with the CEO Roundtable on Cancer can rapidly accelerate the Gold Standard requirements for employers helping to provide a holistic approach to cancer support and best practice navigation for employees,” said Adam Pellegrini, co-founder and CEO of Jasper Health. “Jasper Health will work with CEO Roundtable members to deliver upon the mission of the organization and drive true health outcomes for employers.”
Jasper Health (www.hellojasper.com) is a digital guiding, navigation, and engagement experience that improves the lives of people living with cancer, those at high risk for cancer, and their caregivers. Its all-in-one oncology platform provides psychosocial support interventions while enabling connected care with the broader healthcare system. Their team includes seasoned leaders with decades of experience in digital health, clinical care, data science, and consumer engagement. Founded at Redesign Health, a company that powers innovation in healthcare, they believe that powerful technology and passionate people can relieve some of the stress of organizing care.
The CEO Roundtable mission of eliminating cancer is also a passion of Robert J. Brown, Chief Executive Officer of B&C International.
“We need a lot more vigorous things going on in our communities across the country to deal with cancer,” said Brown, who also serves as an ambassador for the Cancer Gold Standard. “Cancer is a mega problem. It deals with people at every level. I don’t care how poor you are, how rich you are, cancer is there and it’s waiting for you.”
B&C International (BCI) is a Global Strategy and Business Management Consulting firm headquartered in High Point, N.C. During its more than 50 years of existence, the methodologies and tools used by BCI have evolved, but their core principles remain the same. They are trusted advisors. Their systematic approach to aligning culture, communication, and execution, allows clients to gain confidence, clarity and consistency for strategic decision-making.
For more information:
CEO Roundtable on Cancer
Mary Anne Rhyne, Communications Director